Gujarat Themis Biosyn Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 21, 2025, 9:17 am

Quick Insight

Gujarat Themis Biosyn Ltd, a pharmaceutical company, currently trades at a price of 244 with a market capitalization of 2,663 Cr. The company's Price-to-Earnings ratio stands at 50.6, indicating a potentially overvalued stock. However, its Return on Equity is strong at 33.8%, and Return on Capital Employed is robust at 45.0%. With an Operating Profit Margin of 44% and a Net Profit of 59 Cr., the company demonstrates operational efficiency. The high Price-to-Book Value of 12.35x suggests market optimism. Investors should closely monitor this stock for potential corrections given the high valuation metrics and lack of information on key shareholders.

Competitors of Gujarat Themis Biosyn Ltd

All Competitor Stocks of Gujarat Themis Biosyn Ltd

Quarterly Result

Last Updated: August 21, 2025, 9:17 am

Below is a detailed analysis of the quarterly data for Gujarat Themis Biosyn Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 35.87 Cr.. The value appears to be declining and may need further review. It has decreased from 37.74 Cr. (Mar 2025) to 35.87 Cr., marking a decrease of 1.87 Cr..
• For Expenses, as of Jun 2025, the value is 21.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.70 Cr. (Mar 2025) to 21.95 Cr., marking an increase of 0.25 Cr..
• For Operating Profit, as of Jun 2025, the value is 13.92 Cr.. The value appears to be declining and may need further review. It has decreased from 16.04 Cr. (Mar 2025) to 13.92 Cr., marking a decrease of 2.12 Cr..
• For OPM %, as of Jun 2025, the value is 38.81%. The value appears to be declining and may need further review. It has decreased from 42.50% (Mar 2025) to 38.81%, marking a decrease of 3.69%.
• For Other Income, as of Jun 2025, the value is 0.27 Cr.. The value appears to be declining and may need further review. It has decreased from 1.35 Cr. (Mar 2025) to 0.27 Cr., marking a decrease of 1.08 Cr..
• For Interest, as of Jun 2025, the value is 0.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.03 Cr..
• For Depreciation, as of Jun 2025, the value is 2.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.23 Cr. (Mar 2025) to 2.03 Cr., marking an increase of 0.80 Cr..
• For Profit before tax, as of Jun 2025, the value is 12.12 Cr.. The value appears to be declining and may need further review. It has decreased from 16.09 Cr. (Mar 2025) to 12.12 Cr., marking a decrease of 3.97 Cr..
• For Tax %, as of Jun 2025, the value is 25.25%. The value appears to be improving (decreasing) as expected. It has decreased from 25.42% (Mar 2025) to 25.25%, marking a decrease of 0.17%.
• For Net Profit, as of Jun 2025, the value is 9.06 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 9.06 Cr., marking a decrease of 2.94 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.83. The value appears to be declining and may need further review. It has decreased from 1.10 (Mar 2025) to 0.83, marking a decrease of 0.27.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 21, 2025, 9:17 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: August 21, 2025, 9:17 am

Below is a detailed analysis of the balance sheet data for Gujarat Themis Biosyn Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 4.00 Cr..
• For Reserves, as of Mar 2025, the value is 237.00 Cr.. The value appears strong and on an upward trend. It has increased from 194.00 Cr. (Mar 2024) to 237.00 Cr., marking an increase of 43.00 Cr..
• For Borrowings, as of Mar 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3.00 Cr. (Mar 2024) to 30.00 Cr., marking an increase of 27.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 5.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 301.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 221.00 Cr. (Mar 2024) to 301.00 Cr., marking an increase of 80.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 38.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 3.00 Cr..
• For CWIP, as of Mar 2025, the value is 184.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Mar 2024) to 184.00 Cr., marking an increase of 93.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 76.00 Cr.. The value appears to be declining and may need further review. It has decreased from 92.00 Cr. (Mar 2024) to 76.00 Cr., marking a decrease of 16.00 Cr..
• For Total Assets, as of Mar 2025, the value is 301.00 Cr.. The value appears strong and on an upward trend. It has increased from 221.00 Cr. (Mar 2024) to 301.00 Cr., marking an increase of 80.00 Cr..

Notably, the Reserves (237.00 Cr.) exceed the Borrowings (30.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Gujarat Themis Biosyn Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 4.48. This value is below the healthy minimum of 5. It has decreased from 8.14 (Mar 24) to 4.48, marking a decrease of 3.66.
• For Diluted EPS (Rs.), as of Mar 25, the value is 4.48. This value is below the healthy minimum of 5. It has decreased from 8.14 (Mar 24) to 4.48, marking a decrease of 3.66.
• For Cash EPS (Rs.), as of Mar 25, the value is 4.97. This value is within the healthy range. It has decreased from 8.63 (Mar 24) to 4.97, marking a decrease of 3.66.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.79. It has decreased from 27.72 (Mar 24) to 22.79, marking a decrease of 4.93.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.79. It has decreased from 27.72 (Mar 24) to 22.79, marking a decrease of 4.93.
• For Dividend / Share (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has decreased from 1.00 (Mar 24) to 0.67, marking a decrease of 0.33.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 13.84. It has decreased from 23.38 (Mar 24) to 13.84, marking a decrease of 9.54.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 6.54. This value is within the healthy range. It has decreased from 11.44 (Mar 24) to 6.54, marking a decrease of 4.90.
• For PBIT / Share (Rs.), as of Mar 25, the value is 6.05. This value is within the healthy range. It has decreased from 10.95 (Mar 24) to 6.05, marking a decrease of 4.90.
• For PBT / Share (Rs.), as of Mar 25, the value is 6.01. This value is within the healthy range. It has decreased from 10.92 (Mar 24) to 6.01, marking a decrease of 4.91.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 4.48. This value is within the healthy range. It has decreased from 8.14 (Mar 24) to 4.48, marking a decrease of 3.66.
• For PBDIT Margin (%), as of Mar 25, the value is 47.26. This value is within the healthy range. It has decreased from 48.93 (Mar 24) to 47.26, marking a decrease of 1.67.
• For PBIT Margin (%), as of Mar 25, the value is 43.70. This value exceeds the healthy maximum of 20. It has decreased from 46.85 (Mar 24) to 43.70, marking a decrease of 3.15.
• For PBT Margin (%), as of Mar 25, the value is 43.46. This value is within the healthy range. It has decreased from 46.71 (Mar 24) to 43.46, marking a decrease of 3.25.
• For Net Profit Margin (%), as of Mar 25, the value is 32.34. This value exceeds the healthy maximum of 10. It has decreased from 34.83 (Mar 24) to 32.34, marking a decrease of 2.49.
• For Return on Networth / Equity (%), as of Mar 25, the value is 19.63. This value is within the healthy range. It has decreased from 29.37 (Mar 24) to 19.63, marking a decrease of 9.74.
• For Return on Capital Employeed (%), as of Mar 25, the value is 23.47. This value is within the healthy range. It has decreased from 38.82 (Mar 24) to 23.47, marking a decrease of 15.35.
• For Return On Assets (%), as of Mar 25, the value is 16.18. This value is within the healthy range. It has decreased from 26.75 (Mar 24) to 16.18, marking a decrease of 10.57.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.11, marking an increase of 0.11.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.12. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.12, marking an increase of 0.12.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has decreased from 0.87 (Mar 24) to 0.57, marking a decrease of 0.30.
• For Current Ratio (X), as of Mar 25, the value is 2.53. This value is within the healthy range. It has decreased from 2.94 (Mar 24) to 2.53, marking a decrease of 0.41.
• For Quick Ratio (X), as of Mar 25, the value is 2.28. This value exceeds the healthy maximum of 2. It has decreased from 2.74 (Mar 24) to 2.28, marking a decrease of 0.46.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.16. This value is within the healthy range. It has increased from 2.86 (Mar 24) to 6.16, marking an increase of 3.30.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.66 (Mar 24) to 0.00, marking a decrease of 11.66.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.00 (Mar 24) to 0.00, marking a decrease of 11.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.34 (Mar 24) to 0.00, marking a decrease of 88.34.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 89.00 (Mar 24) to 0.00, marking a decrease of 89.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 195.82. This value is within the healthy range. It has decreased from 362.56 (Mar 24) to 195.82, marking a decrease of 166.74.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 134.99. This value is within the healthy range. It has decreased from 259.13 (Mar 24) to 134.99, marking a decrease of 124.14.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,084.71. It has increased from 2,869.27 (Mar 24) to 3,084.71, marking an increase of 215.44.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 20.46. This value exceeds the healthy maximum of 3. It has increased from 16.90 (Mar 24) to 20.46, marking an increase of 3.56.
• For EV / EBITDA (X), as of Mar 25, the value is 43.28. This value exceeds the healthy maximum of 15. It has increased from 34.53 (Mar 24) to 43.28, marking an increase of 8.75.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 20.34. This value exceeds the healthy maximum of 3. It has increased from 16.94 (Mar 24) to 20.34, marking an increase of 3.40.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 88.33 (Mar 24) to 0.00, marking a decrease of 88.33.
• For Price / BV (X), as of Mar 25, the value is 12.35. This value exceeds the healthy maximum of 3. It has decreased from 14.29 (Mar 24) to 12.35, marking a decrease of 1.94.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 20.34. This value exceeds the healthy maximum of 3. It has increased from 16.94 (Mar 24) to 20.34, marking an increase of 3.40.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness